CCHT's "New Drug for Treating Male Children's Developmental Disorders" Sparks Stock Price Surge; Company Responds: Project is Still in Early Stages

Wallstreetcn
2026.02.26 11:18

The clinical trial application for GenSci141 ointment by Changchun High-tech's subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. has been approved, with the indication for improving children's micropenis caused by various reasons. Data shows that this is the world's first drug targeting children's micropenis. Journalists noted that there is limited literature on children's micropenis, and there are global controversies regarding incidence, classification, surgical indications, and surgical age. This has drawn particular market attention to the clinical progress of GenSci141 ointment. Changchun High-tech stated that this project is still in the early stages, and there is currently no information available for external communication. (Everyday Economy)

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer